The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated
